Published in Mol Ther on February 16, 2010
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. J Transl Med (2012) 1.01
Oncolytic Poxviruses. Annu Rev Virol (2014) 0.96
Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med (2011) 0.88
A selectable and excisable marker system for the rapid creation of recombinant poxviruses. PLoS One (2011) 0.82
ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. Mol Ther (2012) 0.82
Replication and Oncolytic Activity of an Avian Orthoreovirus in Human Hepatocellular Carcinoma Cells. Viruses (2017) 0.75
Cowpox Virus: A New and Armed Oncolytic Poxvirus. Mol Ther Oncolytics (2017) 0.75
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86
Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther (2006) 3.09
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 3.06
Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res (2001) 2.68
Oncolytic viruses in cancer therapy. Cancer Lett (2007) 2.45
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol (1995) 2.02
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res (2005) 1.91
VSV-tumor selective replication and protein translation. Oncogene (2005) 1.88
Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol (2003) 1.69
Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther (2007) 1.63
Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res (2009) 1.53
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50
RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog (2008) 1.49
Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther (2000) 1.47
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol (2006) 1.44
Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst (2006) 1.40
Near death experiences: poxvirus regulation of apoptotic death. Virology (2006) 1.27
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2007) 1.16
Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology (1988) 1.14
Adventures with poxviruses of vertebrates. FEMS Microbiol Rev (2000) 1.08
Immunization of black-tailed prairie dog against plague through consumption of vaccine-laden baits. J Wildl Dis (2008) 1.07
Protection of black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption of baits containing recombinant raccoon poxvirus vaccine. Infect Immun (2004) 1.05
Recombinant raccoon pox vaccine protects mice against lethal plague. Vaccine (2003) 1.04
Further characterization of Raccoonpox virus. Arch Virol (1975) 1.03
Why are systemic glioblastoma metastases rare? Systemic and cerebral growth of mouse glioblastoma. Surg Neurol (2005) 1.00
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther (2005) 0.97
Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop. Mol Ther (2008) 0.96
Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection. J Virol (1991) 0.92
Rabies virus antinucleoprotein antibody protects against rabies virus challenge in vivo and inhibits rabies virus replication in vitro. J Virol (1993) 0.90
Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy. J Virol (2001) 0.88
Raccoon poxvirus as a mucosal vaccine vector for domestic cats. J Drug Target (2003) 0.87
Oral vaccination of skunks with raccoon poxvirus recombinants expressing the rabies glycoprotein or the nucleoprotein. J Wildl Dis (1991) 0.86
Prerequisites for oral immunization of free-ranging raccoons (Procyon lotor) with a recombinant rabies virus vaccine: study site ecology and bait system development. J Wildl Dis (1992) 0.85
Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis). Vaccine (2009) 0.84
Identification of the feline herpesvirus type 1 (FHV-1) genes encoding glycoproteins G, D, I and E: expression of FHV-1 glycoprotein D in vaccinia and raccoon poxviruses. J Gen Virol (1994) 0.84
Raccoon poxvirus rabies virus glycoprotein recombinant vaccine in sheep. Arch Virol (1993) 0.84
Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther (2002) 0.83
Protection of cats from infectious peritonitis by vaccination with a recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious peritonitis virus. Adv Exp Med Biol (1995) 0.81
Raccoonpox in a Canadian cat. Vet Dermatol (2006) 0.80
Limited infection upon human exposure to a recombinant raccoon pox vaccine vector. Vaccine (2004) 0.80
Raccoon poxvirus live recombinant feline panleukopenia virus VP2 and rabies virus glycoprotein bivalent vaccine. Vaccine (1997) 0.77
An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell (2003) 15.12
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Poxviruses and immune evasion. Annu Rev Immunol (2001) 4.80
Endothelial cell migration during angiogenesis. Circ Res (2007) 4.67
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer (2005) 3.93
A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity (2005) 3.43
Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol (2004) 2.68
Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol (2004) 2.51
Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med (2004) 2.42
Translational control of the innate immune response through IRF-7. Nature (2008) 2.30
Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol Cell Biol (2006) 2.16
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med (2007) 2.15
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther (2007) 2.14
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell (2011) 1.95
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 1.93
Suppression of PKR promotes network excitability and enhanced cognition by interferon-γ-mediated disinhibition. Cell (2011) 1.89
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
Four-pool modeling of proton exchange processes in biological systems in the presence of MRI-paramagnetic chemical exchange saturation transfer (PARACEST) agents. Magn Reson Med (2008) 1.85
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A (2008) 1.73
Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol (2003) 1.69
Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2009) 1.68
A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther (2008) 1.60
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res (2013) 1.55
Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res (2009) 1.53
Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50
RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog (2008) 1.49
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther (2011) 1.45
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A (2010) 1.39
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther (2011) 1.39
A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther (2010) 1.38
Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst (2006) 1.36
Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther (2004) 1.35
Targeting tumor vasculature with an oncolytic virus. Mol Ther (2011) 1.35
Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak. J Virol (2004) 1.27
The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol (2008) 1.26
Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol (2006) 1.25
Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther (2007) 1.22
Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther (2010) 1.22
Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. J Virol (2005) 1.20
Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell (2007) 1.18
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2007) 1.16
Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR. J Virol (2004) 1.15
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med (2013) 1.13
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther (2013) 1.13
Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res (2012) 1.09
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res (2008) 1.08
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol (2009) 1.06
Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J Neurovirol (2007) 1.06
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res (2008) 1.06
Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria. J Virol (2006) 1.06
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev (2010) 1.06
Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol (2008) 1.06
M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J Virol (2006) 1.05
Complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus. J Virol (2003) 1.05
Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther (2010) 1.05
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther (2012) 1.03
Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther (2009) 1.03
A secreted high-affinity inhibitor of human TNF from Tanapox virus. Proc Natl Acad Sci U S A (2003) 1.02
Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system. Head Neck (2011) 1.02
Internal translation initiation mediated by the angiogenic factor Tie2. J Biol Chem (2005) 1.01
Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res (2012) 1.00
Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. Curr Pharm Biotechnol (2012) 1.00
Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversion-insertion mechanism of EWS-ERG fusion gene formation: a case analysis and literature review. Cancer Genet Cytogenet (2008) 0.99
Internal ribosome entry site-mediated translation of Apaf-1, but not XIAP, is regulated during UV-induced cell death. J Biol Chem (2006) 0.98
Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther (2008) 0.98
CHD1 associates with NCoR and histone deacetylase as well as with RNA splicing proteins. Biochem Biophys Res Commun (2003) 0.98
A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res (2006) 0.98
A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing. ISRN Oncol (2012) 0.97
Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat Commun (2013) 0.97
Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One (2010) 0.97
Chromosomal position effects are linked to sir2-mediated variation in transcriptional burst size. Biophys J (2011) 0.97
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med (2012) 0.96